Linda A. deGraffenried

Author

The University of Texas Health Science Center at San Antonio

Also Known As

Bowers, Laura W., Brenner, Andrew J., DeGraffenried, Linda A., Degraffenried, Linda A., Hursting, Stephen D., Kevin Coombes, Kimler, Bruce F., L A deGraffenried, L deGraffenried, L. A. deGraffenried

146

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio The University of Texas at Austin University of North Carolina at Chapel Hill Pediatrics and Genetics The University of Texas MD Anderson Cancer Center

About

Linda A. deGraffenried is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.4K
2	Cell Biology	14	17	1.3K
3	Health Sciences	4	4	149
4	Biochemistry	1	1	12
5	Cellular Physiology	1	1	66

Linda A. deGraffenried

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity Linda A. deGraffenried, William E. Friedrichs, Douglas Russell, Clinical Cancer Research	2004	384
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Viktor Grünwald, Linda A. deGraffenried, Douglas Russel, PubMed Molecular PharmacologyUrologyChemoprevention StrategyMedicineProstate Cancer Cells	2002	272
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Josep Maria Peralba, Linda A. deGraffenried, William E. Friedrichs, PubMed Mtor-interacting AgentsPharmacodynamic EvaluationPharmacotherapyCell CycleCancer Patients	2003	179
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway Linda A. deGraffenried, Letitia C. Fulcher, William E. Friedrichs, Annals of Oncology Breast OncologySignaling PathwayCell RegulationMedicinePten Expression	2004	174
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling M. Beeram, Qing Tan, RR Tekmal, Annals of Oncology	2007	170
NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen Linda A. deGraffenried, Bysani Chandrasekar, William E. Friedrichs, Annals of Oncology Breast OncologyMedicineImmunologyCancer Cell BiologyBreast Cancer	2004	130
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Shazli N. Malik, Lillian L. Siu, Eric K. Rowinsky, PubMed	2003	130
Cell type-specific and inflammatory-induced expression of haptoglobin gene in lung. Feifei Yang, William E. Friedrichs, A. L. Navarijo-Ashbaugh, PubMed	1995	90
NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin–Aromatase Interactions Laura W. Bowers, Ilane X.F. Maximo, Andrew Brenner, Cancer Research	2014	83
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity Linda A. deGraffenried, William E. Friedrichs, Letitia C. Fulcher, Annals of Oncology Tumor BiologyBreast OncologyMedicineBreast Cancer CellsPharmacology	2003	74

Page 1